Breath alkanes determination in ulcerative colitis and Crohn's disease

被引:67
|
作者
Pelli, MA
Trovarelli, G
Capodicasa, E
De Medio, GE
Bassotti, G
机构
[1] Univ Perugia, Sch Med, Dept Surg & Surg Emergencies, I-06100 Perugia, Italy
[2] Univ Perugia, Sch Med, Inst Internal Med & Oncol Sci, I-06100 Perugia, Italy
[3] Univ Perugia, Sch Med, Inst Biochem & Med Chem, I-06100 Perugia, Italy
[4] Univ Perugia, Sch Med, Gastrointestinal Motil Lab, GI & Hepatol Sect,Dept Clin & Expt Med, I-06100 Perugia, Italy
[5] Univ N Carolina, Div Digest Dis & Nutr, Funct Gastrointestinal Disorders Ctr, Chapel Hill, NC USA
关键词
alkanes; breath test; Crohn's disease; ulcerative colitis;
D O I
10.1007/BF02235186
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: By considering the pathophysiologic basis of inflammatory bowel diseases, a role for excessive lipid peroxidation caused by oxygen free radical compounds has been proposed repeatedly. However, to date only a few studies are available on this topic in human beings. This study was designed to assess breath alkanes in a group of patients with active inflammatory bowel disease by a technique that clearly distinguishes pentane from isoprene, to prevent overestimation of values as in previous studies. PATIENTS: Twenty patients with a diagnosis of active inflammatory bowel disease (10 with Crohn's disease and 10 with ulcerative colitis) were studied. Extension of the disease was similar between patient groups, and all were treated with equivalent doses of steroids and salicylates. METHODS: Breath alkanes determination was performed by a standard procedure involving a gas cromatography column able to separate pentane from isoprene. RESULTS: Overall, significant differences between patients with inflammatory bowel diseases and controls were found for ethane, propane, and pentane, but not for butane and isoprene. Isoprene was clearly distinguished from pentane, demonstrating that the significant elevation of pentane levels in patients with inflammatory bowel diseases is a real phenomenon and not an artifact caused by coelution with isoprene. CONCLUSIONS: An excess of lipid peroxidation is probably an important pathogenetic factor in inflammatory bowel diseases, and this map be assessed through a nonivasive method. Because this method previously also has been shown to be able to evaluate disease activity, it could be a useful tool for studying patients with inflammatory bowel diseases.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [31] Crohn's disease and ulcerative colitis: Antibodies and men
    Duclos, B
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1995, 19 (11): : 865 - 866
  • [32] The Genetics Universe of Crohn's Disease and Ulcerative Colitis
    Parkes, Miles
    DIGESTIVE DISEASES, 2012, 30 : 78 - 81
  • [33] Prevalence of ulcerative colitis and Crohn's disease in Japan
    Asakura, Keiko
    Nishiwaki, Yuji
    Inoue, Nagamu
    Hibi, Toshifumi
    Watanabe, Mamoru
    Takebayashi, Toru
    JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) : 659 - 665
  • [34] Vedolizumab for the treatment of ulcerative colitis and Crohn's disease
    McLean, Leon P.
    Shea-Donohue, Terez
    Cross, Raymond K.
    IMMUNOTHERAPY, 2012, 4 (09) : 883 - 898
  • [35] Immunosuppression therapy in ulcerative colitis and Crohn's disease
    Present, DH
    ADVANCES IN INFLAMMATORY BOWEL DISEASES, 1999, 106 : 218 - 226
  • [36] Probiotics in the Management of Crohn's disease and Ulcerative Colitis
    Muellner, Katalin
    Miheller, Pal
    Herszenyi, Laszlo
    Tulassay, Zsolt
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (28) : 4556 - 4560
  • [37] CT features of ulcerative colitis and Crohn's disease
    Gore, RM
    Balthazar, EJ
    Ghahremani, GG
    Miller, FH
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1996, 167 (01) : 3 - 15
  • [38] Crohn's disease and ulcerative colitis, major similarities
    Dalibon, Pierre
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (545): : 20 - 24
  • [39] Postoperative management of ulcerative colitis and Crohn's disease
    Keswani R.N.
    Cohen R.D.
    Current Gastroenterology Reports, 2005, 7 (6) : 492 - 499
  • [40] The safety of vedolizumab for ulcerative colitis and Crohn's disease
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Rutgeerts, Paul
    Sandborn, William
    Danese, Silvio
    D'Haens, Geert
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Sankoh, Serap
    Fox, Irving
    Parikh, Asit
    Milch, Catherine
    Abhyankar, Brihad
    Feagan, Brian G.
    GUT, 2017, 66 (05) : 839 - 851